Literature DB >> 14673863

Theoretical studies on the mode of inhibition of ribonucleotide reductase by 2'-substituted substrate analogues.

Pedro Alexandrino Fernandes1, Maria João Ramos.   

Abstract

Several 2'-substituted-2'-deoxyribonucleotides are potent time-dependent inactivators of the enzyme ribonucleotide reductase (RNR), which function by destructing its essential tyrosil radical and/or by performing covalent addition to the enzyme. The former leads to inhibition of the R2 dimer of RNR and the latter to inhibition of the R1 dimer. Efforts to elucidate the mechanism of inhibition have been undertaken in the last decades, and a general mechanistic scheme has emerged. Accordingly, two alternative pathways lead either to the inhibition of R1 or R2, for which the 2'-chloro-2'-deoxynucleotides serve as the model for the inhibition of R1 and the 2'-azido-2'-deoxynucleotides the model for the inhibition of R2. However, the underlying reason for the different behavior of the inhibitors has remained unknown until now. Moreover, a fundamental mechanistic alternative has been proposed, based on results from biomimetic reactions, in which the 2'-substituents would be eliminated as radicals, and not as anions, as previously assumed. This would lead to further reactions not predicted by the existing mechanistic scheme. To gain a better understanding we have performed high-level theoretical calculations on the active site of RNR. Results from this work support the general Stubbe's paradigm, although some changes to that mechanism are necessary. In addition, a rational explanation of the factors that determine which of the dimers (R1 or R2) will be inactivated is provided for the first time. It has been demonstrated also that the 2'-substituents are indeed eliminated as anions, and not as radicals. Biomimetic experiments have led to different results because they lack a basic group capable of deprotonating the 3'-HO group of the substrate. It has been found here that the chemical character of the leaving group (radical or anionic) can be manipulated by controlling the protonation state of the 3'-HO group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673863     DOI: 10.1002/chem.200304948

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

Review 1.  Computational studies on class I ribonucleotide reductase: understanding the mechanisms of action and inhibition of a cornerstone enzyme for the treatment of cancer.

Authors:  Susana Pereira; Nuno M F S A Cerqueira; Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  Eur Biophys J       Date:  2005-10-29       Impact factor: 1.733

2.  Dehydration of ribonucleotides catalyzed by ribonucleotide reductase: the role of the enzyme.

Authors:  Nuno M F S A Cerqueira; Pedro Alexandrino Fernandes; Leif A Eriksson; Maria João Ramos
Journal:  Biophys J       Date:  2005-12-16       Impact factor: 4.033

3.  Farnesyltransferase--new insights into the zinc-coordination sphere paradigm: evidence for a carboxylate-shift mechanism.

Authors:  Sérgio F Sousa; Pedro A Fernandes; Maria João Ramos
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

Review 4.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

5.  Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.

Authors:  Edward M Kennedy; Christina Gavegnano; Laura Nguyen; Rebecca Slater; Amanda Lucas; Emilie Fromentin; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

6.  Model Substrate/Inactivation Reactions for MoaA and Ribonucleotide Reductases: Loss of Bromo, Chloro, or Tosylate Groups from C2 of 1,5-Dideoxyhomoribofuranoses upon Generation of an α-Oxy Radical at C3.

Authors:  Stanislaw F Wnuk; Mukesh M Mudgal; Ireneusz Nowak; Morris J Robins
Journal:  Molecules       Date:  2020-05-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.